Brendan L C Kinney, Brianna Brammer, Vikash Kansal, Connor J Parrish, Haydn T Kissick, Yuan Liu, Nabil F Saba, Zachary S Buchwald, Mark W El-Deiry, Mihir R Patel, Brian J Boyce, Azeem S Kaka, Jennifer H Gross, H Michael Baddour, Amy Y Chen, Nicole C Schmitt
{"title":"头颈癌患者的 CD28-CD57+ T 细胞能产生大量细胞毒性颗粒和 II 型干扰素,但不会衰老。","authors":"Brendan L C Kinney, Brianna Brammer, Vikash Kansal, Connor J Parrish, Haydn T Kissick, Yuan Liu, Nabil F Saba, Zachary S Buchwald, Mark W El-Deiry, Mihir R Patel, Brian J Boyce, Azeem S Kaka, Jennifer H Gross, H Michael Baddour, Amy Y Chen, Nicole C Schmitt","doi":"10.1080/2162402X.2024.2367777","DOIUrl":null,"url":null,"abstract":"<p><p>T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (T<sub>EMRA</sub>) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.</p>","PeriodicalId":48714,"journal":{"name":"Oncoimmunology","volume":"13 1","pages":"2367777"},"PeriodicalIF":6.5000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181932/pdf/","citationCount":"0","resultStr":"{\"title\":\"CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.\",\"authors\":\"Brendan L C Kinney, Brianna Brammer, Vikash Kansal, Connor J Parrish, Haydn T Kissick, Yuan Liu, Nabil F Saba, Zachary S Buchwald, Mark W El-Deiry, Mihir R Patel, Brian J Boyce, Azeem S Kaka, Jennifer H Gross, H Michael Baddour, Amy Y Chen, Nicole C Schmitt\",\"doi\":\"10.1080/2162402X.2024.2367777\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (T<sub>EMRA</sub>) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.</p>\",\"PeriodicalId\":48714,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":\"13 1\",\"pages\":\"2367777\"},\"PeriodicalIF\":6.5000,\"publicationDate\":\"2024-06-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11181932/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2024.2367777\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2024.2367777","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
据报道,表达 CD57 和缺乏成本刺激受体 CD27/CD28 的 T 淋巴细胞会随着衰老、慢性感染和癌症而积累。这些细胞被描述为衰老细胞,不能增殖,但细胞溶解和细胞因子生成能力增强。然而,对这些直接取自癌症患者的细胞缺乏强有力的功能研究。我们从 50 位既往未经治疗的头颈部癌症患者的血液和肿瘤样本中分离出了这些 T 细胞及其 CD27/28+ 对应细胞。功能研究证实,这些细胞具有更强的脱颗粒和产生 IFN-γ 的能力。它们还具有增殖能力,因此不会衰老。这些数据表明,CD27/28-CD57+ CD8+ T细胞是高度分化的CD45RA+效应记忆细胞(TEMRA)的一个亚群,具有保留增殖能力。血液中 CD8+ T 细胞中这些细胞的比例大于 34% 的患者局部区域疾病复发率较高,这表明这些细胞可能对预后有重要意义。
CD28-CD57+ T cells from head and neck cancer patients produce high levels of cytotoxic granules and type II interferon but are not senescent.
T lymphocytes expressing CD57 and lacking costimulatory receptors CD27/CD28 have been reported to accumulate with aging, chronic infection, and cancer. These cells are described as senescent, with inability to proliferate but enhanced cytolytic and cytokine-producing capacity. However, robust functional studies on these cells taken directly from cancer patients are lacking. We isolated these T cells and their CD27/28+ counterparts from blood and tumor samples of 50 patients with previously untreated head and neck cancer. Functional studies confirmed that these cells have enhanced ability to degranulate and produce IFN-γ. They also retain the ability to proliferate, thus are not senescent. These data suggest that CD27/28-CD57+ CD8+ T cells are a subset of highly differentiated, CD45RA+ effector memory (TEMRA) cells with retained proliferative capacity. Patients with > 34% of these cells among CD8+ T cells in the blood had a higher rate of locoregional disease relapse, suggesting these cells may have prognostic significance.
期刊介绍:
OncoImmunology is a dynamic, high-profile, open access journal that comprehensively covers tumor immunology and immunotherapy.
As cancer immunotherapy advances, OncoImmunology is committed to publishing top-tier research encompassing all facets of basic and applied tumor immunology.
The journal covers a wide range of topics, including:
-Basic and translational studies in immunology of both solid and hematological malignancies
-Inflammation, innate and acquired immune responses against cancer
-Mechanisms of cancer immunoediting and immune evasion
-Modern immunotherapies, including immunomodulators, immune checkpoint inhibitors, T-cell, NK-cell, and macrophage engagers, and CAR T cells
-Immunological effects of conventional anticancer therapies.